Finding the Best Pharma Stocks to Buy Now: Beyond GLP-1 Hype

The pharmaceutical sector offers compelling opportunities for long-term investors, but current market sentiment is heavily skewed toward a single narrative. When Wall Street latches onto a trend, valuations often disconnect from fundamentals—and right now, the GLP-1 weight loss drug category is commanding excessive premiums. If you’re seeking best pharma stocks to buy now with reasonable valuations, you may need to look beyond the headlines and consider underappreciated alternatives with proven track records.

Why Eli Lilly’s Valuation Poses a Challenge for Value Investors

Eli Lilly deserves credit for its market leadership in GLP-1 therapeutics. Its portfolio of Mounjaro (for diabetes) and Zepbound (for weight loss) represents genuine medical breakthroughs that justify investor enthusiasm. The company demonstrates operational excellence and strong execution.

However, there’s a critical disconnect between Eli Lilly’s business quality and its stock valuation. Trading at a P/E ratio of 51—nearly double the S&P 500’s average of 28—the stock reflects expectations of perpetual growth that may be unrealistic. This valuation assumes Eli Lilly’s GLP-1 dominance remains unchallenged indefinitely.

That assumption is already being tested. Novo Nordisk recently introduced a pill-based version of its GLP-1 drug, addressing a key consumer preference that Eli Lilly’s injection-based offerings don’t satisfy. While Novo Nordisk’s entry doesn’t diminish Eli Lilly’s current position, it demonstrates that market leadership in this category isn’t guaranteed. A competitor’s drug could gain traction quickly, eroding Eli Lilly’s premium valuation almost overnight. For investors prioritizing value over momentum, this risk is difficult to ignore.

Overlooked Pharma Leaders: Finding Best Pharma Stocks to Buy Now in Merck and Bristol Myers Squibb

The pharmaceutical industry extends far beyond GLP-1 treatments. Major drugmakers like Merck and Bristol Myers Squibb maintain diversified pipelines addressing substantial market opportunities that receive minimal attention from today’s GLP-1-obsessed investor base.

Merck’s Multi-Faceted Portfolio: Merck’s research efforts span cardiometabolic therapies, oncology, and infectious disease treatments—all critical areas of ongoing medical need. Bristol Myers Squibb similarly maintains strength across cardiovascular therapeutics, cancer treatments, and immunology. These aren’t niche businesses; they represent some of the largest and most stable profit centers in modern medicine.

The Patent Cliff Factor: A legitimate concern for both companies is the approaching expiration of certain blockbuster drug patents. When patent protection lapses, revenues can decline sharply—a phenomenon known as the “patent cliff.” This reality explains why these companies currently fly under investor radar. However, patent cliffs are a predictable industry cycle, not an existential threat.

Both Merck and Bristol Myers Squibb have demonstrated over decades that they can innovate through these transitions. Their historical ability to develop replacement drugs before revenue collapse has made them reliable long-term performers. This requires patience and conviction, but it’s the hallmark of successful pharmaceutical investing.

The Valuation Advantage: Here lies the compelling investment case. Merck trades at a P/E ratio of just over 14, while Bristol Myers Squibb sits at 18. These multiples offer dramatically better value than Eli Lilly’s premium. Combined with their proven research capabilities and diversified revenue streams, both companies represent best pharma stocks to buy now for value-conscious investors.

Evaluating Price Against Fundamentals in Pharma Investments

The distinction between price and value defines successful stock selection. Eli Lilly operates at peak efficiency and currently dominates its market niche—there’s nothing fundamentally broken about the business. The issue is purely valuation: Wall Street has priced in years of uninterrupted GLP-1 dominance at a level that leaves minimal room for competitive threats or slower growth.

In contrast, Merck and Bristol Myers Squibb carry valuations that reflect investor skepticism about near-term patent cliff challenges. This pessimism creates an opportunity for contrarian investors willing to trust in the innovation capabilities of well-established pharmaceutical companies.

The choice ultimately depends on your investment philosophy. If you prioritize paying a fair price for quality assets and maintaining a margin of safety, best pharma stocks to buy now likely exclude Eli Lilly’s richly valued shares. Instead, they point toward Merck and Bristol Myers Squibb—overlooked companies with comparable research pedigrees, diversified businesses, and compelling valuations.

Long-term pharmaceutical investing rewards patience, conviction in R&D capabilities, and disciplined valuation discipline. The market’s current obsession with GLP-1 treatments has inadvertently created an opportunity to buy overlooked quality at discounted prices.